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E-mail address: amanda.wood@mcri.edu.au (A.G. WAutosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a nonlesional condition associated with
mutation of the gene coding for the a4 nicotinic acetylcholine receptor (nAChR). The nAChR modulates
aspects of memory and attention. We examined the neuropsychological phenotype of ADNFLE, with a
particular emphasis on understanding the impact on frontal lobe functions. We used standard clinical
tests as well as focused measures of frontal lobe function in a well-deﬁned group of patients with ADN-
FLE. Their performance was compared with that of a group of age-, sex-, and education-matched control
participants. Patients with ADNFLE showed impairments on tasks requiring cognitive ﬂexibility against a
background of well-preserved intellectual abilities. In accord with existing research, verbal memory
impairments were identiﬁed in the patient group; the level of impairment on these tasks correlated with
disease-related factors. In our study of ADNFLE associated with one mutation, cognitive ﬂexibility
appears to be the core cognitive deﬁcit.
Crown Copyright  2010 Published by Elsevier Inc. All rights reserved.1. Introduction experimental animals appears to be on memory processing [6,13],Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
was theﬁrst epilepsy syndrome forwhichageneticbasiswasdiscov-
ered, and several nicotinic receptor subunit gene mutations have
nowbeen reported [1–3].Neuronalnicotinic acetylcholine receptors
(nAChRs) are heteropentamers of a(2–10) and b(2–4) subunits and
are widespread throughout the brain. Initial human and animal evi-
dence of a role for these receptors in fundamental and higher-level
aspects of cognition has been reported, but a deﬁnitive view is yet
to emerge. Administration of nicotine to abstinent smokers
improves general alertness, attention, and vigilance [4,5]. Nicotine
improves performance on vigilance tasks [6,7], inhibition of prepo-
tent responses [8], and verbal learning [9] in nonsmokers. Effects
suchas these, however, are thought to reﬂect an inﬂuenceongeneral
alertness, rather than the primary inﬂuence of speciﬁc cognitive
domains [10,11]. Administrationof nicotineor nicotinicdrugsmight
also facilitateattentionandmemory inpatientswithdementiaof the
Alzheimer type [12]. The predominant effect of nAChR ligands in010 Published by Elsevier Inc. All r
t, Level 2, Royal Children’s
Fax: +61 3 9345 4325.
ood).and the a7 and a4b2 receptors have been implicated in mediating
these effects [5].
In the current study we examined individuals with a missense
mutation, S248F, of the CHRNA4 gene that encodes the a4 subunit
of the nAChR [3,14]. Patients with this mutation have ADNFLE, a
distinctive syndrome associated with mutations of three acetyl-
choline receptor subunit genes, CHRNA4, CHRNB2, CHRNA2, in dif-
ferent families [15]. The majority of mutations have been found
in CHRNA4. Patients with ADNFLE experience clusters of nocturnal
seizures arising from the frontal lobes [14], and reduced right pre-
frontal receptor density and hypometabolism are observed on PET
[16]. The frontal lobe aspects of the disorder raise the possibility
that associated cognitive dysfunction may be observed. Research
on a pair of monozygotic twins with a mutation of the b2 nAChR
found impaired verbal memory abilities [17]. Recent data on a
group of 11 patients with known nAChR subunit mutations (three
CHRNA4 and one CHRNB2 mutation) [16] showed impaired mem-
ory and executive function as well as impaired intellectual abilities
in 5 patients.
The aim of the current study was to characterize neurocognitive
function in patients with ADNFLE caused by the same CHRNA4
mutation, tapping a range of functions that are heavily dependentights reserved.
532 A.G. Wood et al. / Epilepsy & Behavior 17 (2010) 531–535on frontal lobe integrity. We hypothesized that aspects of executive
function would be impaired in the patient group.
2. Materials and methods
2.1. Participants
Inclusion criteria were a conﬁrmed mutation of the CHRNA4
(S248F) gene, English as theﬁrst language, andabsence of other neu-
rological or cognitive disorders. Clinical features of the nine eligible
participants from a single large family [14,18] are summarized in
Table 1. At the current assessment, a detailed clinical history and
neurological examination were obtained by M.F. and I.E.S., and the
participants’ medical records were reviewed and the most recent
carbamazepine serum level (usually within 2 days of testing) was
obtained. Data recorded included age at seizure onset and offset,
weekly seizure frequency estimated over the duration of the illness
and at the time of testing, antiepileptic medication at the time of
assessment and most recent drug levels, and smoking status. Two
investigators (I.E.S., S.F.B.) reviewed the medical details and rated
the epilepsy as mild or severe. This rating was used as a measure
of the impact of the disease at the time patients had active seizures.
Patientswhowere seizure freewithorwithout theuseofmedication
were categorized as having mild epilepsy; those with ongoing
seizures despite medication or a history of greater than 15 years of
seizures were regarded as having severe epilepsy. At the time of
assessment all but one participant with ADNFLE was seizure free
(see Table 1), and six participants with ADNFLE took antiepileptic
medication (carbamazepine in 6, additional clonazepam in 1). The
average age at seizure onset was 7.2 years (range: 5–12), and
seizures occurred for an average of 23.2 years (range: 2–54). The
average number of seizures per week during that time was 10.3
(range: 5–40).
To control for intrafamily effects independent of themutationwe
calculated thedegreeof relatedness, a coefﬁcientof theproportionof
genetic identity shared between members of the pedigree and a
proband. For example, 50%of the proband’s genome is shared by sib-
lings and parents, yielding a relatedness coefﬁcient of 0.5. A group of
age-, sex-, and education-matched control participants were
recruited. There were two males in each group. All participants
providedwritten informed consent, in accordancewith institutional
andAustralianNationalHealth andMedical ResearchCouncil guide-
lines. Ethical approval was provided by the Austin Health Human
Research Ethics Committee.
2.2. Cognitive measures
Verbal ﬂuency was measured using the standard clinical admin-
istration of the Controlled Oral Word Association Test (COWAT)Table 1
Clinical and demographic characteristics of participants with the mutation.
Pedigree referencea Age at assessment Age at onset (years) Duration (years)
IV-22 62 7 48
IV-27 63 6 54
V-3 43 7 34
V-4 41 5 10
V-12d 37 6 31
V-15 33 5 12
V-28 38 6 12
V-33 28 12 6
VI-7e 16 11 2
a Pedigree references refer to Fig. 3 in Steinlein et al. [3].
b Seizure frequency was obtained through medical interview.
c CBZ, carbamazepine; CLN, clonazepam.
d Ongoing seizures at the time of assessment.
e VI-7 mutation status was conﬁrmed subsequent to earlier publications.(see Strauss et al. [19]). The cognitive demands and neural sub-
strate of this task are well described [20,21]. The measure used
here was the total number of words retrieved for the letters F, A,
and S.
To examine in detail aspects of frontal lobe function, we devel-
oped measures using in-house programming (either EPrime or
matlab), and all tasks were presented on a laptop computer. The
ability to inhibit a prepotent response was measured using Col-
or–Word Interference (Stroop task). The task comprised 120 trials
in which a single word was presented on the screen. Incongruent
trials (i.e., where the color word and the font’s color did not match)
constituted 30% of the trials. Participants named the font color as
quickly as possible, and accuracy and reaction time were measured
using software developed in matlab (Version 6, The Mathworks).
Vigilance (sustained attention) was measured by assessing
accuracy of performance over 15 minutes while participants
pressed a button in response to single letters presented on the lap-
top screen. Two trial types were recorded. Target trials required
participants to press one key each time a letter was seen on the
screen. ‘‘Change” trials occurred infrequently (18%) and required
an alternative button press when the letter that was presented
was ‘c’, and it was preceded by the letter ‘x’, and they were in dif-
ferent colors. Thus, the task required monitoring of the n  1 item’s
features (akin to n-back working memory), inhibition of a prepo-
tent motor response, which, although slightly modiﬁed, resembles
a go/no go task, as well as vigilance. Accuracy was measured across
the length of the task and within four equal time epochs.
Delayed match-to-sample is a task requiring participants to se-
lect a previously presented target stimulus from a group of distrac-
tors. Here we used a short delay of 2 seconds. In our task, a
complex pictorial target was shown on a screen and, 2 seconds la-
ter, was presented again with three ‘‘foil” stimuli that shared either
color or pattern features. The short delay period meant that this
task relied more heavily on immediate attention rather than mem-
ory processing.
Attentional set shifting during a rule learning task was assessed
using a paradigm based on intradimensional and extradimensional
set shifting [22]. Participants viewed a computer screen on which
three boxes were presented, from left to right across the screen.
On each trial, two of three boxes on the screen contained a stimu-
lus comprising three features (animal, shape, color). Participants
were instructed that there was a rule they needed to learn, based
on those features, and that after each trial they would be provided
feedback to assist their learning. Responses were made using one
of three sequential buttons on the keyboard, which corresponded
to the position of the boxes on the screen. After each response,
feedback (correct/incorrect) was provided visually on the screen
and the trial was repeated if incorrect. After eight correct re-
sponses, the rule changed and the participant was required toSeizure frequency (weekly)b AEDs at time of interview Disease severity
5 CBZc Severe
5 CBZ Severe
5 CBZ + CLN Severe
5 — Mild
40 CBZ Severe
12 CBZ Mild
10 — Mild
1 — Mild
10 CBZ Mild
A.G. Wood et al. / Epilepsy & Behavior 17 (2010) 531–535 533adapt to the new rule requirements. Measures included the total
number of errors made, total number of trials to successfully nego-
tiate the overall task, as well as number of errors and number of
trials to criterion for each rule learned.
One of the rules within the set shifting task was akin to object
alternation, where the correct choice from two displayed items
changed from trial to trial. This task is typically employed in re-
ward-based learning paradigms in human and nonhuman primate
literature. In our task, theparticipantwas requirednot only to detect
the feature (animal, shape, or color) onwhich the rulewasbased, but
also to determine that this changed between two of the three op-
tions. The number of incorrect responses and the total number of
trials to criterion (eight correct in sequence) were recorded.
To exclude the possibility that performance on these very sen-
sitive tasks reﬂected group differences in general intellectual abil-
ities, we used the four-subtest version of theWechsler Abbreviated
Scale of Intelligence (WASI) [23] as a measure of Full Scale IQ. Fur-
thermore, we sought to establish whether the group with ADNFLE
exhibited a frontal lobe-type syndrome through clinical interview
and quantitative screening of neurobehavioral features using the
Frontal Assessment Battery [24]. Participants with ADNFLE were
also assessed on standard tasks of memory including the Rey Audi-
tory Verbal Learning Test (RAVLT), and visual memory was as-
sessed using Rey’s Complex Figure (30-minute delay protocol;
see Lezak et al. [25]). z score statistics were computed for these
tasks; RAVLT normative data were derived from Geffen et al.
[26], and for Rey’s Complex Figure we used data from Spreen and
Strauss [27]. Audioverbal attention (Digit Span from Wechsler
Adult Intelligence Scale, Third Edition (WAIS-3)) [28] and working
memory (Letter Number Sequencing from the WAIS-3) were also
assessed in the patient group. The Trail Making Test is a widely
used clinical task that provides a measure of basic psychomotor
speed (Trails A) and assesses mental set shifting abilities (Trails
B). Normative data cited in Spreen and Strauss [27] were used to
establish the performance of patients with ADNFLE.
2.3. Statistical analysis
Independent t tests were used to compare the patient and con-
trol groups on cognitive measures (using a criterion of P < 0.05,
two-tailed). For any cognitive task showing a difference between
the groups, we then examined performance by the patients on that
task in relation to epilepsy variables. For continuous variables (age
at seizure onset, duration of epilepsy, weekly seizure frequency,
drug levels), we used correlation analysis. To identify and rule
out cognitive variables with even a trend toward being inﬂuenced
by disease variables, we used a threshold of P = 0.1. For dichoto-
mous variables (medication status, seizure severity, smoking sta-
tus) independent t tests were used with a threshold of P = 0.1.
This conservative approach was taken to carefully exclude the pos-
sibility that the differences between the groups were due to dis-
ease factors.Fig. 1. Those with the CHRNA4 S248F mutation performed signiﬁcantly more poorly
on the object alternation task, with a threefold increase in the average number of
attempts (error bars represent SE) required to learn the rule and a concomitant
increase in the number of errors made during the task.3. Results
The nine patients and nine controls were well matched on age
and general intellectual abilities (all P > 0.05). The mean age of
the mutation group was 40.1 years (SD = 15.0, range = 16–63),
and that for controls was 39.3 years (SD = 14.6, range = 15–64).
3.1. Performance by patients on standard clinical neuropsychological
measures
Full Scale IQ fell within the ‘‘average” range for both groups
(mutation group: 94.0 ± 11.8, mean ± SD; control group:97.7 ± 9.5). Theaverage score of patientswithADNFLEon theFrontal
Assessment Battery (15.4 ± 1.5) was within normal limits. Perfor-
mance on standard clinical tasks was evaluated against established
normative data. Participants with ADNFLE performed lower than
average on RAVLT total recall (z score, Trials 1–5: 1.4 ± 1.0) and
post-interference recall (Trial 6: 1.4 ± 1.4). Performance on the
RAVLTwas related to the serum level of carbamazepine (RAVLTTrial
6 scores: r = 0.8, P = 0.01; RAVLT total scores: r = 0.8, P = 0.02).
Digit Span scaled scores were, on average, 6.8 ± 2.2. Letter Number
Sequencing scaled scores (7.0 ± 2.9) were signiﬁcantly better in
thosewith ‘‘mild”diseaseversus thosewhoseepilepsywasclassiﬁed
as ‘‘severe” (t[6] = 2.6, P = 0.04). Delayed recall of Rey’s Complex Fig-
urewaswithin normal limits across the group (z score = 0.3 ± 1.2).
Performance on Part B of the Trail Making Test, which measures set
shiftingusingapsychomotor component, in thosewith themutation
was 1.4 SD above the populationmean, indicating that performance
was slower than expected. Performance on this variable was not re-
lated to any disease variable. Trails A performance was within nor-
mal limits (mean = 0.65, SD = 1.25).
3.2. Performance by the groups on frontal lobe measures
Performance on several tasks differed signiﬁcantly between the
groups. Here we present data on those measures where no associ-
ation between disease variables and performance by the patient
group was identiﬁed. We adopted this approach to ensure that
group differences represented ADNFLE-speciﬁc ﬁndings rather
than effects due to the treatment or severity of epilepsy per se.
Patients with ADNFLE performed more poorly on the object alter-
nation phase of the set-shifting paradigm, using almost twice as
many attempts to learn the rule to criterion than controls (Fig. 1)
(t[16] = 2.12, P = 0.05). Performance was characterized by vari-
ability in rule learning, reﬂected by an almost threefold increase
in error rate (t[16] = 2.33, P = 0.03). The pattern of results reﬂects
the participants’ difﬁculty in modifying their erroneous responses
to this complex and cognitively challenging task, which relies on
the ability to shift and factor in feedback on a trial-by-trial basis.
This was also consistent with the formal evaluation of response
inhibition using our computerized version of the Stroop test. Sig-
niﬁcantly more errors on incongruent trials of the Stroop color-
naming task were seen in those with the mutation (t[16] = 3.93,
P = 0.001), despite the two groups’ similar levels of accuracy on
congruent trials (t[16] = 1.71, P = 0.11) (Fig. 2). Verbal ﬂuency per-
formance fell within the average range for control participants, but
Fig. 2. Performance on COWAT was in the average range for controls, but
signiﬁcantly worse in patients with the CHRNA4 S248F mutation. The proportion
of correct incongruent trials on the Stroop Color–Word interference task was also
signiﬁcantly worse in those with the mutation than in controls. Scores are mean
values and error bars represent SE.
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P = 0.01). The number of trials performed correctly on the delayed
matching-to-sample task was similar for the two groups.
The measure of vigilance that we employed comprised a contin-
uous performance element (measuring sustained attention) as well
as a more demanding requirement to change response set at
random, infrequent time points throughout (akin to a go/no go
paradigm). Task performance can be collapsed across the entire
15 minutes or divided into time epochs of equal duration. The latter
approach permits a closer analysis of change in attention over time.
First, examining the overall performance across all trials showed
that performance on the sustained attention component differed
between the groups (e.g., total percentage correct: t[15] = 3.7,
P = 0.002), but, in patients with ADNFLE, was signiﬁcantly worse in
patients whose epilepsy was rated as severe (t[6] = 2.1, P = 0.08)
and in those still on medication (t[6] = 2.7, P = 0.03). A signiﬁcant
correlation with serum level of medication and total percentage
correct was also identiﬁed (r = 0.7, P = 0.05). Trials on which
participants had to change their responses based on the sequence
of presented items demanded higher order cognitive skills. The
total percentage correct on all such ‘‘change” trials did not differ
between patients with ADNFLE and matched controls (‘‘change”
trials: t[15] = 0.97, P = 0.35), and repeated-measures analysis of the
four epochs did not reach statistical signiﬁcance (F[3.45] = 2.4,
P = 0.07).
4. Discussion
In contrast to previous research in patients with ADNFLE, our
study involves a single group, which was homogeneous with re-
spect to the underlying causative mutation. Family members with
the S248F CHRNA4 subunit mutation were impaired on tasks that
require ﬂexible adaptation to, and monitoring of, cognitive de-
mands. In particular, performance was impaired on Color–Word
Interference, object alternation, Controlled Oral Word Association
Test, and Part B of the Trail Making Test, implicating a frontal lobe
dysfunction. General intellectual function was normal, suggesting
that the cognitive difﬁculties identiﬁed cannot be attributed to a
global impairment. Like others, we identiﬁed memory difﬁculties
in this cohort, but showed that these relate to the severity of dis-
ease-related variables or medications.
Performance on the frontal lobe tasks in the patient group was
independent of seizure severity, medication, or smoking. An intra-familial genetic effect, other than the mutation of interest, seems
unlikely as defects did not depend on the degree of relatedness
in this large pedigree [14]. A more deﬁnitive evaluation of this
question could be achieved by studying mutation-negative family
members, but this was not possible in the current study. This is
an interesting area for future research. The cognitive proﬁle in
our patients is similar to that seen in lesional frontal lobe epilepsy
[29]. In our patient group, however, there is no detectable lesion on
MRI. On balance, the lack of association between impaired
cognitive ﬂexibility and familial factors, seizure effects, epilepsy
treatment, or nicotine exposure increases the likelihood of a
gene-speciﬁc effect. Converging evidence could be obtained in fu-
ture studies by investigating the effects of nAChR agonists or
antagonists on cognitive ﬂexibility in patients with the mutation.
In previous research on CHRNA4 mutations, visuospatial atten-
tion ‘‘scaling” was better in those with a greater number of C alleles
in the CHRNA4 C1545T single-nucleotide polymorphism (SNP)
[30,31]. Visuospatial attention scaling refers to the modiﬁcation
of an attentional focus in the visual ﬁeld on the basis of prior infor-
mation. The authors describe it as ‘‘a ﬂexibly deployed gradient
that can be dynamically constricted or expanded . . . according to
task demands” ([30], p. 3.) This paradigm bears a class relationship
to the tasks that we used, lending weight to our hypothesis that
core executive functions are supported by the a4 receptor.
In accord with our study, executive dysfunction has also been
demonstrated in four families with a4 subunit mutations, S252L
and T265I, as well as S248F [16]. Like the current study, verbal
learning impairments have been identiﬁed previously in patients
with ADNFLE. This included patients with S248F mutation [16]
and twins with a novel mutation of the b2 nAChR [17]. The latter
had signiﬁcant impairments of general intellectual skills and other
aspects of verbal functions. Further, a mother and daughter with a
CHRNB2 mutation and relatively intact intellectual skills [32]
showed memory impairments, as well as set shifting difﬁculties.
In the group studied here, verbal learning, audioverbal span, and
working memory performances were correlated with disease
and/or treatment variables, preventing, or rendering less likely, a
direct causal link between these measures and mutations in
ADNFLE.
Since our original description of ADNFLE, greater variability in
the general intellectual proﬁle of patients with nAChR subunit
mutations has been recognized. This variability may be family,
and thus presumably nAChR gene mutation, dependent. Cho and
colleagues described a different family with ADNFLE (CHRNA4
mutation) and markedly impaired general intellectual skills [33].
Similarly, we found that severe ADNFLE can be associated with
marked psychiatric disability and intellectual impairment [34].
The molecular mechanisms underlying different intellectual out-
comes are not yet understood. The current study also found that
the group performed within the normal range on the Frontal
Assessment Battery. This bedside screening measure was designed
for the detection of frontal lobe syndrome arising from destructive
frontal lobe disease (injury, hemorrhages, degeneration, etc.). Our
patients do not present with a clinically evident frontal lobe syn-
drome; hence our use of sophisticated high-level cognitive para-
digms to illustrate the effects of receptor level dysfunction in
ADNFLE.
There is nowan emerging literature describing cognitive abilities
in patientswithADNFLE anddifferentmutations. The cognitive phe-
notype appears to be variable, although the association between
cognitive performance and epilepsy-related variables has not al-
ways been examined. Although previous authors have speculated
about links between mutation and speciﬁc cognitive domains [16],
we agree that it is premature to draw such conclusions. Indeed, be-
fore concluding that there may be a speciﬁc phenotype associated
with ADNFLE, it is important to ﬁrst examine secondary factors that
A.G. Wood et al. / Epilepsy & Behavior 17 (2010) 531–535 535mayexplaincognitiveﬁndings.Althoughwecannot ruleout thepos-
sibility that disease variables may, at least in part, explain our re-
sults, an important focus of our study was the careful examination
of available disease variables in relation to task performance. A char-
acteristic of ADNFLE is frequent, brief, nocturnal seizures that dis-
turb normal sleep. Only one of our participants with the mutation
continued to have seizures at the time of assessment, minimizing
any effects of chronic sleep loss on our ﬁndings. The focal nature of
the impairment in patients with a4 mutations is consistent with
the in vivo ﬁnding of reduced prefrontal nAChR binding [35], and
contrasts with the widespread physiological distribution of a4b2
nAChRs [5]. Accordingly, we conclude that cognitive ﬂexibility is a
core component of the neuropsychological phenotype associated
with mutations causing ADNFLE. Additional research examining
the impact of the gene on the developing brain and cognitive skill
acquisition is warranted.
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